Chimerix, Inc.
Viés de alta

CMRX $2.10 in cash and no debt / enough to sustain through 2026

smart investors / Insiders are buying as well / year end tax loss harvesting is almost done and I believe biotechs will run fast in jan / feb
Beyond Technical AnalysisFundamental AnalysisTechnical Indicators

Aviso legal